ASCO: Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors
ABSTRACTS: 3000 and 3005
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate promising responses and safety profiles in heavily pretreated patients with advanced solid tumors. The studies were featured in an oral abstract session highlighting the development of new molecularly targeted...

AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with...
MD Anderson expands breakthrough research campus with groundbreaking of innovative new facility
The University of Texas MD Anderson Cancer Center today broke ground on a 600,000-square-foot facility intended to anchor the institution’...
Research identifies new potential hurdle for nano-based therapies
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.
The researchers found age-related differences are due to how effectively the liver filters the bloodstream. Younger livers are more efficient at this...

MD Anderson applauds NCI’s National Cancer Plan
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework...
MD Anderson and Xilis announce strategic collaboration to advance novel technology and accelerate therapeutic development
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
Eyal Gottlieb, Ph.D., to join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
MD Anderson celebrates World Cancer Research Day
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight...
MD Anderson Research Highlights for July 27, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...